Please login to the form below

Not currently logged in
Email:
Password:

BMS-986205

This page shows the latest BMS-986205 news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Bristol-Myers Squibb hammered another nail in the coffin of IDO1 as a drug target in immuno-oncology yesterday after halting two trials of its BMS-986205 candidate acquired

Latest news

  • BMS boosts immuno-oncology with $2.3bn IFM buy BMS boosts immuno-oncology with $2.3bn IFM buy

    The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and LAG-3 (BMS-986016) - all in phase ... Adding the new candidates "broadens our ability to investigate

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics